Clinical Trial Update: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adjuvant zoledronic acid in high-risk Giant Cell Tumor of Bone has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Giant Cell Tumor of Bone, Osteoclastoma | Phase 2 | Status: TERMINATED